Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab versus placebo after curative resection or ablation for hepatocellular carcinoma at high risk of recurrence
NL-OMON59629Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of nivolumab in hepatocellular carcinoma (HCC), sponsored by Bristol Myers Squibb. Started Dec 2019; status: completed.
02
Drugs
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NL-OMON59629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59629.